Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H17ClN2O3S |
| Molecular Weight | 388.868 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=CC2=C1C(SC3=CC=C(Cl)C=C3)=C(C)N2CC(O)=O
InChI
InChIKey=JWYIGNODXSRKGP-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)
| Molecular Formula | C19H17ClN2O3S |
| Molecular Weight | 388.868 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://openinnovation.astrazeneca.com/azd1981.htmlCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23827726
Sources: https://openinnovation.astrazeneca.com/azd1981.html
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23827726
AZD-1981, developed by AstraZeneca, is a potent (binding IC50 of 4nM), fully reversible, functionally non-competitive antagonist of human CRTh2. It blocks agonist-induced human eosinophil CD11b expression, shape change (including in whole blood), and chemotaxis as well as an basophil shape change and Th2-cell chemotaxis at IC50's of 8.5-50nM. Potency is similar across species as is plasma protein binding (~97%). AZD-1981 is a weak (10s of μM) inhibitor in vitro of CYP2C9, OATP1B1 and UGT1A1 as well as an inducer of CYP3A4. AZD-1981 was well tolerated and no safety concerns were identified.There was no beneficial clinical effect of AZD-1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD. AZD-1981 has being discontinued for asthma and chronic obstructive pulmonary disease. AstraZeneca is collaborating with Johns Hopkins University for the development of AZD-1981 in the treatment of chronic idiopathic urticaria. It is in phase II clinicals studies for the treatment of Urticaria.
CNS Activity
Sources: https://ncats.nih.gov/files/AZD1981.pdf
Curator's Comment: AZD1981 has low CNS penetration and, thus, is probably not suitable for a CNS indication
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5071 Sources: https://ncats.nih.gov/files/AZD1981.pdf |
4.3 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9030 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27558866 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AZD-1981 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18900 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27558866 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
AZD-1981 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://ncats.nih.gov/files/AZD1981.pdf
AZD-1981 has been administered orally in healthy volunteers (single oral dose up to 4,000 mg; multiple doses up to 2,000 mg
twice daily [BID] for 2 wks), asthma or COPD patients (up to 100 mg, BID for 4 wks), and asthmatics (up to 400 mg BID for 12
wks).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21944852
AZD-1981 inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:57:21 GMT 2025
by
admin
on
Mon Mar 31 19:57:21 GMT 2025
|
| Record UNII |
2AD53WQ2CX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11292191
Created by
admin on Mon Mar 31 19:57:21 GMT 2025 , Edited by admin on Mon Mar 31 19:57:21 GMT 2025
|
PRIMARY | |||
|
100000174982
Created by
admin on Mon Mar 31 19:57:21 GMT 2025 , Edited by admin on Mon Mar 31 19:57:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL1914489
Created by
admin on Mon Mar 31 19:57:21 GMT 2025 , Edited by admin on Mon Mar 31 19:57:21 GMT 2025
|
PRIMARY | |||
|
DTXSID901025620
Created by
admin on Mon Mar 31 19:57:21 GMT 2025 , Edited by admin on Mon Mar 31 19:57:21 GMT 2025
|
PRIMARY | |||
|
2AD53WQ2CX
Created by
admin on Mon Mar 31 19:57:21 GMT 2025 , Edited by admin on Mon Mar 31 19:57:21 GMT 2025
|
PRIMARY | |||
|
DB11946
Created by
admin on Mon Mar 31 19:57:21 GMT 2025 , Edited by admin on Mon Mar 31 19:57:21 GMT 2025
|
PRIMARY | |||
|
802904-66-1
Created by
admin on Mon Mar 31 19:57:21 GMT 2025 , Edited by admin on Mon Mar 31 19:57:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |